Pacira Biosciences

Update in progress

PCRX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Pacira BioSciences, Inc. develops, manufactures, markets, distributes, and sells non-opioid pain management and regenerative health solutions for U.S. healthcare practitioners. Its products include EXPAREL (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA (triamcinolone acetonide extended-release) for osteoarthritis knee pain, and the iovera system for targeted cryoanalgesia. It is also developing PCRX-201 gene therapy. The company is based in Brisbane, California, and formerly operated as Pacira Pharmaceuticals. It has a NOCITA collaboration with Aratana.

Company score

Sentiment: 0.23; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.12; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive